Citations (213)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (53)
Gianni Ghetti, Lorenzo Pradelli, Giannis Papageorgiou, George Karpouzos & Yelda Arikan. (2023) CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece. ClinicoEconomics and Outcomes Research 15, pages 97-109.
Read now
Read now
Robert Gerald Jan Moes, Eline L Huisman, Samuel JP Malkin & Barnaby Hunt. (2023) Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands. ClinicoEconomics and Outcomes Research 15, pages 87-96.
Read now
Read now
Sasha Berry, Barrie Chubb, Annabel Acs, Edel Falla, Akanksha Verma, Samuel J. P. Malkin, Barnaby Hunt & Andrew J. Palmer. (2023) Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide. Journal of Medical Economics 26:1, pages 1019-1031.
Read now
Read now
Lijuan Zhang, Xuefei Leng, Fei Tian, Dunming Xiao, Jianwei Xuan, Hongxiu Yang, Jing Liu & Zhihong Chen. (2022) Cost-effectiveness analysis of continuous subcutaneous insulin infusion versus multiple daily insulin for treatment of children with type 1 diabetes. Postgraduate Medicine 134:6, pages 627-634.
Read now
Read now
Stephane Roze, John J Isitt, Jayne Smith-Palmer & Peter Lynch. (2021) Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. ClinicoEconomics and Outcomes Research 13, pages 717-725.
Read now
Read now
Stéphane Roze, Maria Ida Buompensiere, Zeynep Ozdemir, Simona de Portu & Ohad Cohen. (2021) Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK. Journal of Medical Economics 24:1, pages 883-890.
Read now
Read now
Johan Jendle, Åsa Ericsson, Bertil Ekman, Stefan Sjöberg, Jens Gundgaard, João da Rocha Fernandes, Ann-Charlotte Mårdby, Barnaby Hunt, Samuel J. P. Malkin & Maria Thunander. (2020) Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. Journal of Medical Economics 23:11, pages 1311-1320.
Read now
Read now
Juan José Gorgojo-Martínez, Samuel J. P. Malkin, Virginia Martín, Nino Hallén & Barnaby Hunt. (2020) Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. Journal of Medical Economics 23:2, pages 193-203.
Read now
Read now
Stephen C. Bain, Brian Bekker Hansen, Barnaby Hunt, Barrie Chubb & William J. Valentine. (2020) Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. Journal of Medical Economics 23:1, pages 98-105.
Read now
Read now
Johannes Pöhlmann, Roberta Montagnoli, Giusi Lastoria, Witesh Parekh, Marie Markert & Barnaby Hunt. (2019) Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy. ClinicoEconomics and Outcomes Research 11, pages 605-614.
Read now
Read now
Stephané Roze, Jayne Smith-Palmer, Simona de Portu, Alexis Delbaere, Bonnie de Brouwer & Harold W de Valk. (2019) Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands. ClinicoEconomics and Outcomes Research 11, pages 73-82.
Read now
Read now
Michael Dempsey, Michelle Mocarski, Jakob Langer & Barnaby Hunt. (2018) Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of Medical Economics 21:11, pages 1110-1118.
Read now
Read now
Bjoern Schwander, Mark Nuijten, Mickaël Hiligsmann & Silvia M.A.A. Evers. (2018) Event simulation and external validation applied in published health economic models for obesity: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 18:5, pages 529-541.
Read now
Read now
Marek Psota, Maria Bucek Psenkova, Natalia Racekova, Antonio Ramirez de Arellano, Tom Vandebrouck & Barnaby Hunt. (2017) Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. ClinicoEconomics and Outcomes Research 9, pages 749-762.
Read now
Read now
Unchalee Permsuwan, Kednapa Thavorn, Piyameth Dilokthornsakul, Surasak Saokaew & Nathorn Chaiyakunapruk. (2017) Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective. Journal of Medical Economics 20:9, pages 991-999.
Read now
Read now
B. Hunt, M. Mocarski, W. J. Valentine & J. Langer. (2017) Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. Journal of Medical Economics 20:7, pages 663-670.
Read now
Read now
Tatiana Dilla, Dimitra Alexiou, Ismini Chatzitheofilou, Ruba Ayyub, Julia Lowin & Kirsi Norrbacka. (2017) The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2. Journal of Medical Economics 20:5, pages 443-452.
Read now
Read now
Lena Landstedt-Hallin, Jens Gundgaard, Åsa Ericsson & Susanne Ellfors-Zetterlund. (2017) Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Current Medical Research and Opinion 33:4, pages 647-655.
Read now
Read now
Unchalee Permsuwan, Piyameth Dilokthornsakul, Kednapa Thavorn, Surasak Saokaew & Nathorn Chaiyakunapruk. (2017) Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. Journal of Medical Economics 20:2, pages 171-181.
Read now
Read now
Unchalee Permsuwan, Piyameth Dilokthornsakul, Surasak Saokaew, Kednapa Thavorn & Nathorn Chaiyakunapruk. (2016) Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand. ClinicoEconomics and Outcomes Research 8, pages 521-529.
Read now
Read now
S. Roze, E. Duteil, J. Smith-Palmer, S. de Portu, W. Valentine, B. F. E. de Brouwer, Y. Reznik & H. W. de Valk. (2016) Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. Journal of Medical Economics 19:8, pages 742-749.
Read now
Read now
Stéphane Roze, Jayne Smith-Palmer, William J. Valentine, Mark Cook, Manisha Jethwa, Simona de Portu & John C. Pickup. (2016) Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective. Journal of Medical Economics 19:3, pages 236-242.
Read now
Read now
Ronan Roussel, Luc Martinez, Tom Vandebrouck, Habiba Douik, Patrick Emiel, Matthieu Guery, Barnaby Hunt & William J. Valentine. (2016) Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics 19:2, pages 131-144.
Read now
Read now
Charles Andy Schuetz, Siew Hwa Ong & Matthias Blüher. (2015) Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. ClinicoEconomics and Outcomes Research 7, pages 313-323.
Read now
Read now
Jing Deng, Shuyan Gu, Hui Shao, Hengjin Dong, Dajin Zou & Lizheng Shi. (2015) Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies. Journal of Medical Economics 18:11, pages 974-989.
Read now
Read now
Pernilla Huetson, James L. Palmer, Andrée Levorsen, Marie Fournier, Maeva Germe & Euan McLeod. (2015) Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. Journal of Medical Economics 18:8, pages 573-585.
Read now
Read now
Marc Evans, Phil McEwan & Volker Foos. (2015) Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation. Journal of Medical Economics 18:2, pages 96-105.
Read now
Read now
Michael Willis, Christian Asseburg & Jianming He. (2013) Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). Journal of Medical Economics 16:8, pages 1007-1021.
Read now
Read now
Tiago Fonseca, John Clegg, Giuseppe Caputo, Kirsi Norrbacka, Tatiana Dilla & Maria Alvarez. (2013) The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m2 in Spain. Journal of Medical Economics 16:7, pages 926-938.
Read now
Read now
Won Chan Lee, Yevgeniy Samyshkin, Jakob Langer & James L. Palmer. (2012) Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. Journal of Medical Economics 15:sup2, pages 28-37.
Read now
Read now
Yevgeniy Samyshkin, Anne-Laure Guillermin, Jennie H. Best, Steven C. Brunell & Adam Lloyd. (2012) Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. Journal of Medical Economics 15:sup2, pages 6-13.
Read now
Read now
J. Smith-Palmer, C. Fajardo-Montañana, R. F. Pollock, A. Ericsson & W. J. Valentine. (2012) Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics 15:5, pages 977-986.
Read now
Read now
Richard F. Pollock, Bradley H. Curtis & William J. Valentine. (2012) A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. Journal of Medical Economics 15:4, pages 766-775.
Read now
Read now
Anne-Laure Guillermin, Adam Lloyd, Jennie H. Best, Mary Beth DeYoung, Yevgeniy Samyshkin & Julia Aledort Gaebler. (2012) Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. Journal of Medical Economics 15:4, pages 654-663.
Read now
Read now
Vasil Valov, James Palmer, Marcin Czech, Alexandra Savova & Guenka Petrova. (2012) Cost-Effectiveness of Biphasic Insulin Aspart 30 VS. Human Premix Insulin in Type 2 Diabetes from the Payer's Perspective in Bulgaria. Biotechnology & Biotechnological Equipment 26:2, pages 2937-2944.
Read now
Read now
Christian Becker, Astrid Langer & Reiner Leidl. (2011) The quality of three decision-analytic diabetes models: a systematic health economic assessment. Expert Review of Pharmacoeconomics & Outcomes Research 11:6, pages 751-762.
Read now
Read now
W.C. Lee, C. Conner & M. Hammer. (2011) Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Current Medical Research and Opinion 27:5, pages 897-906.
Read now
Read now
Amélie Beaudet, James L. Palmer, Louise Timlin, Bernard Wilson, David Bruhn, Kristina S. Boye & Adam Lloyd. (2011) Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. Journal of Medical Economics 14:3, pages 357-366.
Read now
Read now
Anne-Laure Guillermin, Yevgeniy Samyshkin, Donna Wright, Tini Nguyen & Julie Villeneuve. (2011) Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. Journal of Medical Economics 14:2, pages 207-216.
Read now
Read now
Y. Yi, Z. Philips, G. Bergman & K. Burslem. (2010) Economic models in type 2 diabetes. Current Medical Research and Opinion 26:9, pages 2105-2118.
Read now
Read now
James L. Palmer, Martin S. Knudsen, Mark Aagren & Trine L. Thomsen. (2010) Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. Journal of Medical Economics 13:2, pages 212-220.
Read now
Read now
William J. Valentine, Richard F. Pollock, Juliette Plun-Favreau & Jeremy White. (2010) Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Current Medical Research and Opinion 26:6, pages 1399-1412.
Read now
Read now
Sandra L. Tunis, William D. Willis & Volker Foos. (2010) Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain. Current Medical Research and Opinion 26:1, pages 163-175.
Read now
Read now
Sandra L. Tunis & Michael E. Minshall. (2010) Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US. Current Medical Research and Opinion 26:1, pages 151-162.
Read now
Read now
Meaghan St. Charles, Michael E. Minshall, Bhavik J. Pandya, Robert W. Baran & Sandra L. Tunis. (2009) A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. Current Medical Research and Opinion 25:6, pages 1343-1353.
Read now
Read now
Sandra L. Tunis, Michael E. Minshall, Christopher Conner, John I. McCormick, Jovana Kapor, Jean-François Yale & Danielle Groleau. (2009) Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Current Medical Research and Opinion 25:5, pages 1273-1284.
Read now
Read now
Manuela Helena Gschwend, Mark Aagren & William J Valentine. (2009) Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. Journal of Medical Economics 12:2, pages 114-123.
Read now
Read now
Sandra L. Tunis, Michael E. Minshall, Meaghan St. Charles, Bhavik J. Pandya & Robert W. Baran. (2008) Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US
. Current Medical Research and Opinion 24:11, pages 3085-3096.
Read now
Read now
James L. Palmer, Gordon Goodall, Steffen Nielsen, Robert W. Kotchie, William J. Valentine, Andrew J. Palmer & Stéphane Roze. (2008) Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Current Medical Research and Opinion 24:5, pages 1417-1428.
Read now
Read now
Mohammed Ali, Jeremy White, Chen-Hui Lee, James L Palmer, Jayne Smith-Palmer, Walid Fakhoury & William J Valentine. (2008) Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. Journal of Medical Economics 11:4, pages 651-670.
Read now
Read now
Jens Sandahl Christiansen. (2007) Insulin aspart: rapid control for postmeal glucose excursions. Expert Review of Endocrinology & Metabolism 2:5, pages 587-597.
Read now
Read now
Joshua A. Ray, Kristina S. Boye, Nicole Yurgin, William J. Valentine, Stéphane Roze, Jan McKendrick, Daniel M. D. Tucker, Volker Foos & Andrew J. Palmer. (2007) Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Current Medical Research and Opinion 23:3, pages 609-622.
Read now
Read now
Stéphane Roze, William J. Valentine, Thomas Evers & Andrew J. Palmer. (2006) Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. Current Medical Research and Opinion 22:7, pages 1415-1424.
Read now
Read now
Articles from other publishers (160)
Johan Jendle, Maria Ida BuompensiereAsli Zeynep Ozdemir SaltikSimona de PortuJayne Smith-Palmer, Richard F. PollockOhad Cohen. (2023) A European Cost–Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes. Diabetes Technology & Therapeutics 25:12, pages 864-876.
Crossref
Crossref
Ran Wei, Weihao Wang, Xiusheng Huang, Jingtao Qiao, Jinghe Huang, Chang Xing, Qi Pan & Lixin Guo. (2023) Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients. Diabetology & Metabolic Syndrome 15:1.
Crossref
Crossref
Carlo Bruno Giorda, Antonio Rossi, Fabio Baccetti, Rita Zilich, Francesco Romeo, Nreu Besmir, Graziano Di Cianni, Giacomo Guaita, Lelio Morviducci, Marco Muselli, Alessandro Ozzello, Federico Pisani, Paola Ponzani, Pierluigi Santin, Damiano Verda & Nicoletta Musacchio. (2023) Achieving Good Metabolic Control Without Weight Gain with the Systematic Use of GLP-1-RAs and SGLT-2 Inhibitors in Type 2 Diabetes: A Machine-learning Projection Using Data from Clinical Practice. Clinical Therapeutics 45:8, pages 754-761.
Crossref
Crossref
Hamza Alshannaq, Greg Cogswell, Richard F. Pollock, Waqas Ahmed, Greg J. Norman, Peter M. Lynch & Stephane Roze. (2023) Cost‐utility of real‐time continuous glucose monitoring versus self‐monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark. Diabetes, Obesity and Metabolism.
Crossref
Crossref
Marc Evans, Sasha Berry, Samuel J. P. Malkin, Barnaby Hunt & Abheet Sharma. (2023) Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK. Diabetes Therapy 14:6, pages 1005-1021.
Crossref
Crossref
Marc Evans, Barrie Chubb, Samuel J. P. Malkin, Sasha Berry, Jack Lawson & Barnaby Hunt. (2022)
Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the
UK
: A long‐term cost‐effectiveness analysis based on
SUSTAIN
11
. Diabetes, Obesity and Metabolism 25:2, pages 491-500.
Crossref
Crossref
Samuel J. P. Malkin, Davide Carvalho, Catarina Costa, Vasco Conde & Barnaby Hunt. (2022) The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Diabetology & Metabolic Syndrome 14:1.
Crossref
Crossref
John J. Isitt, Stéphane Roze, Helen Sharland, Greg Cogswell, Hamza Alshannaq, Gregory J. Norman & Peter M. Lynch. (2022) Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK. Diabetes Therapy 13:11-12, pages 1875-1890.
Crossref
Crossref
Qiong Luo, Li Zhou, Naitong Zhou & Ming Hu. (2022) Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes. Frontiers in Public Health 10.
Crossref
Crossref
Michael A. Rotondi, Octavia Wong, Michael Riddell & Bruce Perkins. (2022) Population-Level Impact and Cost-effectiveness of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring Technologies for Adults With Type 1 Diabetes in Canada: A Modeling Study. Diabetes Care 45:9, pages 2012-2019.
Crossref
Crossref
J. J. Isitt, S. Roze, D. Tilden, N. Arora, A. J. Palmer, T. Jones, D. Rentoul & P. Lynch. (2022) Long‐term cost‐effectiveness of Dexcom G6 real‐time continuous glucose monitoring system in people with type 1 diabetes in Australia. Diabetic Medicine 39:7.
Crossref
Crossref
Hailey Saunders, Ba’ Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, Silkan K. Bains, Margaret Jamieson, Donna Plett, Srushhti Trivedi, Catherine H. Yu, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review. Value in Health 25:7, pages 1235-1252.
Crossref
Crossref
Sajad Emamipour, Eva Pagano, Daniela Di Cuonzo, Stefan R. A. Konings, Amber A. van der Heijden, Petra Elders, Joline W. J. Beulens, Jose Leal & Talitha L. Feenstra. (2022) The transferability and validity of a population-level simulation model for the economic evaluation of interventions in diabetes: the MICADO model. Acta Diabetologica 59:7, pages 949-957.
Crossref
Crossref
Vaia LambadiariAsli Zeynep Ozdemir SaltikSimona de PortuMaria Ida BuompensiereAikaterini KountouriEmmanouil KorakasHelen Sharland & Ohad Cohen. (2022) Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece. Diabetes Technology & Therapeutics 24:5, pages 316-323.
Crossref
Crossref
Erik H. Serné, Stéphane Roze, Maria I. Buompensiere, William J. Valentine, Simona De Portu & Harold W. de Valk. (2022) Cost-Effectiveness of Hybrid Closed Loop Insulin Pumps Versus Multiple Daily Injections Plus Intermittently Scanned Glucose Monitoring in People With Type 1 Diabetes in The Netherlands. Advances in Therapy 39:4, pages 1844-1856.
Crossref
Crossref
Lars H. Ehlers, Mark Lamotte, Mafalda C. Ramos, Susanne Sandgaard, Pia Holmgaard, Malene M. Kristensen & Niels Ejskjaer. (2022) The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark. Diabetes Therapy 13:3, pages 489-503.
Crossref
Crossref
Xinjun Jiang, Hua Jiang, Libo Tao & Mingzi Li. (2021) The Cost-Effectiveness Analysis of Self-Efficacy-Focused Structured Education Program for Patients With Type 2 Diabetes Mellitus in Mainland China Setting. Frontiers in Public Health 9.
Crossref
Crossref
Marko Krstic, Jean-Christophe Alain Devaud & Farshid Sadeghipour. (2021) Pharmacists’ considerations on non-medical switching at the hospital: a systematic review of the economic outcomes of cost-saving therapeutic drug classes. European Journal of Hospital Pharmacy 28:e1, pages e2-e7.
Crossref
Crossref
Johan Jendle, M. I. Buompensiere, A. L. Holm, S. de Portu, S. J. P. Malkin & O. Cohen. (2021) The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. Diabetes Therapy 12:11, pages 2977-2991.
Crossref
Crossref
L. Si, J. A. Eisman, T. Winzenberg, K. M. Sanders, J. R. Center, T. V. Nguyen, T. Tran & A. J. Palmer. (2021) Development and validation of the risk engine for an Australian Health Economics Model of Osteoporosis. Osteoporosis International 32:10, pages 2073-2081.
Crossref
Crossref
Emma G Wilmot, Mark Evans, Katharine Barnard-Kelly, M Burns, Iain Cranston, Rachel Ann Elliott, G Gkountouras, N Kanumilli, A Krishan, C Kotonya, S Lumley, P Narendran, Sankalpa Neupane, Gerry Rayman, Christopher Sutton, V P Taxiarchi, H Thabit & L Leelarathna. (2021) Flash glucose monitoring with the FreeStyle Libre 2 compared with self-monitoring of blood glucose in suboptimally controlled type 1 diabetes: the FLASH-UK randomised controlled trial protocol. BMJ Open 11:7, pages e050713.
Crossref
Crossref
Margareta Hellgren, Ann‐Marie Svensson, Stefan Franzén, Åsa Ericsson, Soffia Gudbjörnsdottir, Nils Ekström, Rebecka Bertilsson, William Valentine & Samuel Malkin. (2021)
The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in
Sweden
: A health economic modelling analysis based on nationwide data
. Diabetes, Obesity and Metabolism 23:7, pages 1604-1613.
Crossref
Crossref
Michael Willis, Christian Asseburg, April Slee, Andreas Nilsson & Cheryl Neslusan. (2021) Macrovascular Risk Equations Based on the CANVAS Program. PharmacoEconomics 39:4, pages 447-461.
Crossref
Crossref
Elizabeth Wehler, Dominik Lautsch, Stacey Kowal, Glenn Davies, Andrew Briggs, Qianyi Li, Swapnil Rajpathak & Adnan Alsumali. (2020) Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin. PharmacoEconomics 39:3, pages 317-330.
Crossref
Crossref
Matthew Capehorn, Nino Hallén, James Baker-Knight, Divina Glah & Barnaby Hunt. (2021) Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting. Diabetes Therapy 12:2, pages 537-555.
Crossref
Crossref
Stéphane Roze, John J. Isitt, Jayne Smith-Palmer, Peter Lynch, Brigitte Klinkenbijl, Gerald Zammit & Pierre-Yves Benhamou. (2020) Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France. Diabetes Therapy 12:1, pages 235-246.
Crossref
Crossref
Virginia Martín, Josep Vidal, Samuel J. P. Malkin, Nino Hallén & Barnaby Hunt. (2020) Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Advances in Therapy 37:10, pages 4427-4445.
Crossref
Crossref
Mafalda Ramos, Michael H. Cummings, Anastasia Ustyugova, Syed I. Raza, Shamika U. de Silva & Mark Lamotte. (2020) Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK. Diabetes Therapy 11:9, pages 2041-2055.
Crossref
Crossref
Peng Men, Shuli Qu, Zhenqiang Song, Yanjun Liu, Chaoyun Li & Suodi Zhai. (2020) Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost–Utility Analysis. Diabetes Therapy 11:8, pages 1745-1755.
Crossref
Crossref
Pierre Johansen, Barrie Chubb, Barnaby Hunt, Samuel J. P. Malkin, Anna Sandberg & Matthew Capehorn. (2020) Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Advances in Therapy 37:5, pages 2427-2441.
Crossref
Crossref
Wenhui Jiang, Jingyu Wang, Xiaofang Shen, Wenli Lu, Yuan Wang, Wen Li, Zhongai Gao, Jie Xu, Xiaochen Li, Ran Liu, Miaoyan Zheng, Bai Chang, Jing Li, Juhong Yang & Baocheng Chang. (2020) Establishment and Validation of a Risk Prediction Model for Early Diabetic Kidney Disease Based on a Systematic Review and Meta-Analysis of 20 Cohorts. Diabetes Care 43:4, pages 925-933.
Crossref
Crossref
Sarah Naz Ali, Tam Dang-Tan, William J. Valentine & Brian Bekker Hansen. (2020) Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States. Advances in Therapy 37:2, pages 869-882.
Crossref
Crossref
Peng Men, Shuli Qu, Wenting Luo, Chaoyun Li & Suodi Zhai. (2019) Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta‐analysis and cost‐effectiveness analysis. Diabetes, Obesity and Metabolism 22:1, pages 107-115.
Crossref
Crossref
Stephen C. Bain, Brian B. Hansen, Samuel J. P. Malkin, Solomon Nuhoho, William J. Valentine, Barrie Chubb, Barnaby Hunt & Matthew Capehorn. (2019) Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. Diabetes Therapy 11:1, pages 259-277.
Crossref
Crossref
Svetlana V. Doubova, Stephane Roze, Aldo Ferreira-Hermosillo, Ricardo Pérez-Cuevas, Ricardo Gasca-Pineda, Casper Barsoe, Jonathan Baran, Brian Ichihara, Erick Gryzbowski, Kyla Jones & Juan E. Valencia. (2019) Cost-effectiveness of the use of the continuous subcutaneous insulin infusion pump versus daily multiple injections in type 1 diabetes adult patients at the Mexican Institute of Social Security. Cost Effectiveness and Resource Allocation 17:1.
Crossref
Crossref
E. Lau, A. Salem, J. C. N. Chan, W. Y. So, A. Kong, M. Lamotte & A. Luk. (2019) Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis. Cost Effectiveness and Resource Allocation 17:1.
Crossref
Crossref
Stéphane RozeJayne Smith-PalmerSimona de PortuA. Zeynep Özdemir SaltikTuğba AkgülOğuzhan Deyneli. (2019) Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey. Diabetes Technology & Therapeutics 21:12, pages 727-735.
Crossref
Crossref
Massimiliano Copetti, Hetal Shah, Andrea Fontana, Maria Giovanna Scarale, Claudia Menzaghi, Salvatore De Cosmo, Monia Garofolo, Maria Rosaria Sorrentino, Olga Lamacchia, Giuseppe Penno, Alessandro Doria & Vincenzo Trischitta. (2019) Estimation of Mortality Risk in Type 2 Diabetic Patients (ENFORCE): An Inexpensive and Parsimonious Prediction Model. The Journal of Clinical Endocrinology & Metabolism 104:10, pages 4900-4908.
Crossref
Crossref
Barnaby Hunt, Samuel J P Malkin, Robert G J Moes, Eline L Huisman, Tom Vandebrouck & Bruce H R Wolffenbuttel. (2019) Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Research & Care 7:1, pages e000705.
Crossref
Crossref
Anna Hung, Julia F. Slejko, Amy Lugo, Fadia Shaya, Stuart T. Haines & C. Daniel Mullins. (2019) Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study. Journal of Managed Care & Specialty Pharmacy 25:8, pages 913-921.
Crossref
Crossref
Peter Gæde, Pierre Johansen, Christian Klyver Tikkanen, Richard Fulton Pollock, Barnaby Hunt & Samuel Joseph Paul Malkin. (2019) Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Therapy 10:4, pages 1297-1317.
Crossref
Crossref
Samuel J. P. Malkin, Monika Russel-Szymczyk, Marek Psota, Lucia Hlavinkova & Barnaby Hunt. (2019) The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Advances in Therapy 36:8, pages 2034-2051.
Crossref
Crossref
Pedro Mezquita Raya, Francisco Javier Ampudia Blasco, Barnaby Hunt, Virginia Martin, Brian Larsen Thorsted, Amaury Basse & Hermione Price. (2019) Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence. Diabetes, Obesity and Metabolism 21:6, pages 1349-1356.
Crossref
Crossref
Manjiri Pawaskar, S. Pinar Bilir, Stacey Kowal, Claudio Gonzalez, Swapnil Rajpathak & Glenn Davies. (2019) Cost‐effectiveness of intensification with sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom. Diabetes, Obesity and Metabolism 21:4, pages 1010-1017.
Crossref
Crossref
Stephané Roze, Jayne Smith-Palmer, Alexis Delbaere, Karita Bjornstrom, Simona de Portu, William Valentine & Mikko Honkasalo. (2019) Cost-Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland. Diabetes Therapy 10:2, pages 563-574.
Crossref
Crossref
Johannes Pöhlmann, Monika Russel-Szymczyk, Pavel Holík, Karel Rychna & Barnaby Hunt. (2019) Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi. Diabetes Therapy 10:2, pages 493-508.
Crossref
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Crossref
Adie Viljoen, Christina S. Hoxer, Pierre Johansen, Samuel Malkin, Barnaby Hunt & Stephen C. Bain. (2018) Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes, Obesity and Metabolism 21:3, pages 611-621.
Crossref
Crossref
Johan JendleJohannes PöhlmannSimona de PortuJayne Smith-PalmerStéphane Roze. (2019) Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. Diabetes Technology & Therapeutics 21:3, pages 110-118.
Crossref
Crossref
Lei Si, John A Eisman, Tania Winzenberg, Kerrie M Sanders, Jacqueline R Center, Tuan V Nguyen & Andrew J Palmer. (2019) Microsimulation model for the health economic evaluation of osteoporosis interventions: study protocol. BMJ Open 9:2, pages e028365.
Crossref
Crossref
Samuel J. P. Malkin, Monika Russel-Szymczyk, Girtel Liidemann, Vallo Volke & Barnaby Hunt. (2018) Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Diabetes Therapy 10:1, pages 159-176.
Crossref
Crossref
Anthony H. Barnett, Simon Arnoldini, Barnaby Hunt, Gowri Subramanian & Christina Stentoft Hoxer. (2018) Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. Diabetes, Obesity and Metabolism 20:8, pages 1921-1927.
Crossref
Crossref
A. Nicolucci, M.C. Rossi, D. D'Ostilio, A. Delbaere, S. de Portu & S. Roze. (2018) Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. Nutrition, Metabolism and Cardiovascular Diseases 28:7, pages 707-715.
Crossref
Crossref
Limin Wang, Qing Ye, Ole Kjerkegaard Nielsen, Anne Gadegaard, William J. Valentine, Barnaby Hunt & Linhong Wang. (2018) Evaluation of the Long-Term Impact of Improving Care for People with Type 2 Diabetes in China. Value in Health Regional Issues 15, pages 169-174.
Crossref
Crossref
Mickael Basson, Dionysios Ntais, Ruba Ayyub, Donna Wright, Julia Lowin, Florence Chartier, Stéphane Roze & Kirsi Norrbacka. (2017) The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France. Diabetes Therapy 9:1, pages 13-25.
Crossref
Crossref
David Russell‐Jones, Simon R. Heller, Sarah Buchs, Anna Sandberg, William J. Valentine & Barnaby Hunt. (2017)
Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the
UK
setting
. Diabetes, Obesity and Metabolism 19:12, pages 1773-1780.
Crossref
Crossref
Milan Kvapil, Martin Prázný, Pavel Holik, Karel Rychna & Barnaby Hunt. (2017) Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic. Diabetes Therapy 8:6, pages 1331-1347.
Crossref
Crossref
Johan Jendle, Jayne Smith-Palmer, Alexis Delbaere, Simona de Portu, Natalie Papo, William Valentine & Stéphane Roze. (2017) Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden. Diabetes Therapy 8:5, pages 1015-1030.
Crossref
Crossref
Isaac Corro Ramos, George A.K. van Voorn, Pepijn Vemer, Talitha L. Feenstra & Maiwenn J. Al. (2017) A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data. Value in Health 20:8, pages 1041-1047.
Crossref
Crossref
Barnaby Hunt, Divina Glah & Maarten van der Vliet. (2017) Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands. Diabetes Therapy 8:4, pages 753-765.
Crossref
Crossref
Barnaby Hunt, Nana Kragh, Ceilidh C. McConnachie, William J. Valentine, Maria C. Rossi & Roberta Montagnoli. (2017) Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide. Clinical Therapeutics 39:7, pages 1347-1359.
Crossref
Crossref
Barnaby Hunt, Gabriela Vega-Hernandez, William J. Valentine & Nana Kragh. (2017) Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes, Obesity and Metabolism 19:6, pages 842-849.
Crossref
Crossref
Arti Appannah, Toni Rice & Rajna Ogrin. (2017) A review of current models for initiating injectable therapy for people with type 2 diabetes in primary care. Journal of Clinical & Translational Endocrinology 8, pages 54-61.
Crossref
Crossref
S. Roze, S. de Portu, J. Smith-Palmer, A. Delbaere, W. Valentine & M. Ridderstråle. (2017) Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark. Diabetes Research and Clinical Practice 128, pages 6-14.
Crossref
Crossref
Barnaby Hunt, Michelle Mocarski, William J. Valentine & Jakob Langer. (2017) IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes Therapy 8:3, pages 531-544.
Crossref
Crossref
Gabriela Vega-Hernandez, Radek Wojcik & Max Schlueter. (2017) Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK. Diabetes Therapy 8:3, pages 513-530.
Crossref
Crossref
Behnam Sharif, Hubert Wong, Aslam H. Anis & Jacek A. Kopec. (2017) A Practical ANOVA Approach for Uncertainty Analysis in Population-Based Disease Microsimulation Models. Value in Health 20:4, pages 710-717.
Crossref
Crossref
Pedro Mezquita-Raya, Antonio Ramírez de Arellano, Nana Kragh, Gabriela Vega-Hernandez, Johannes Pöhlmann, William J. Valentine & Barnaby Hunt. (2017) Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Therapy 8:2, pages 401-415.
Crossref
Crossref
L. Schoumacker-Ley, L. Duchesne, T. Cuny, P. B?hme, S. Benzirar, R. Fay, O. Ziegler & B. Guerci. (2017) Optimisation du contr?le glyc?mique chez les patients diab?tiques de type 1 par Mesure Continue du Glucose (MCG) et arr?t pr?dictif de la pompe : r?sultats de l??tude OMEGA. M?decine des Maladies M?taboliques 11:2, pages 137-147.
Crossref
Crossref
Michael Willis, Pierre Johansen, Andreas Nilsson & Christian Asseburg. (2016) Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). PharmacoEconomics 35:3, pages 375-396.
Crossref
Crossref
Barnaby Hunt, Qing Ye, William J. Valentine & Donna Ashley. (2017) Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom. Diabetes Therapy 8:1, pages 129-147.
Crossref
Crossref
Ana Maria Gomez, Rafael Alfonso-Cristancho, John Jairo Orozco, Peter Matthew Lynch, Diana Prieto, Rhodri. Saunders, Stephane Roze & Juan Esteban Valencia. (2016) Beneficios cl?nicos y econ?micos de la terapia con bomba de insulina integrada a sistema de monitoreo continuo de glucosa en los pacientes diab?ticos tipo 1 en Colombia. Endocrinolog?a y Nutrici?n 63:9, pages 466-474.
Crossref
Crossref
Ana Maria Gomez, Rafael Alfonso-Cristancho, John Jairo Orozco, Peter Matthew Lynch, Diana Prieto, Rhodri Saunders, Stephane Roze & Juan Esteban Valencia. (2016) Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia. Endocrinología y Nutrición (English Edition) 63:9, pages 466-474.
Crossref
Crossref
Klea Panayidou, Sandro Gsteiger, Matthias Egger, Gablu Kilcher, Máximo Carreras, Orestis Efthimiou, Thomas P. A. Debray, Sven Trelle & Noemi Hummel. (2016) GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world. Research Synthesis Methods 7:3, pages 264-277.
Crossref
Crossref
Stephanie J. Fonda, Claudia Graham, Julie Munakata, Julia M. Powers, David Price & Robert A. Vigersky. (2016) The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes. Journal of Diabetes Science and Technology 10:4, pages 898-904.
Crossref
Crossref
Xuesong Zhang, Sisi Liu, Yukun Li, Yan Wang, Meimei Tian & Guoqiang Liu. (2016) Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study. PLOS ONE 11:6, pages e0156393.
Crossref
Crossref
Martin Henriksson, Ramandeep Jindal, Catarina Sternhufvud, Klas Bergenheim, Elisabeth Sörstadius & Michael Willis. (2016) A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus. PharmacoEconomics 34:6, pages 569-585.
Crossref
Crossref
Unchalee Permsuwan, Nathorn Chaiyakunapruk, Piyameth Dilokthornsakul, Kednapa Thavorn & Surasak Saokaew. (2016) Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand. Applied Health Economics and Health Policy 14:3, pages 281-292.
Crossref
Crossref
Rob Riemsma, Isaac Corro Ramos, Richard Birnie, Nasuh Büyükkaramikli, Nigel Armstrong, Steve Ryder, Steven Duffy, Gill Worthy, Maiwenn Al, Johan Severens & Jos Kleijnen. (2016) Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. Health Technology Assessment 20:17, pages 1-252.
Crossref
Crossref
Stéphane RozeJayne Smith-PalmerWilliam ValentineVincent PayetSimona de PortuNatalie PapoMichel CucheratHelene Hanaire. (2016) Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France. Diabetes Technology & Therapeutics 18:2, pages 75-84.
Crossref
Crossref
Barnaby Hunt, José Luis Aguilar Garza, Carlos Jesús Enríquez Vázquez, Pavika Jain & William J. Valentine. (2015) Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico. Value in Health Regional Issues 8, pages 20-27.
Crossref
Crossref
Jason P. Gordon, Marc Evans, Jorge Puelles & Philip C. McEwan. (2015) Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy. Diabetes Therapy 6:4, pages 495-507.
Crossref
Crossref
Simone Marini, Emanuele Trifoglio, Nicola Barbarini, Francesco Sambo, Barbara Di Camillo, Alberto Malovini, Marco Manfrini, Claudio Cobelli & Riccardo Bellazzi. (2015) A Dynamic Bayesian Network model for long-term simulation of clinical complications in type 1 diabetes. Journal of Biomedical Informatics 57, pages 369-376.
Crossref
Crossref
S. Wolowacz, I. Pearson, P. Shannon, B. Chubb, J. Gundgaard, M. Davies & A. Briggs. (2015) Development and validation of a cost-utility model for Type?1 diabetes mellitus. Diabetic Medicine 32:8, pages 1023-1035.
Crossref
Crossref
Pamela Royle, Hema Mistry, Peter Auguste, Deepson Shyangdan, Karoline Freeman, Noemi Lois & Norman Waugh. (2015) Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Health Technology Assessment 19:51, pages 1-248.
Crossref
Crossref
L. Si, T. M. Winzenberg, Q. Jiang, M. Chen & A. J. Palmer. (2015) Projection of osteoporosis-related fractures and costs in China: 2010?2050. Osteoporosis International 26:7, pages 1929-1937.
Crossref
Crossref
L. Si, T. M. Winzenberg, Q. Jiang & A. J. Palmer. (2015) Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model. Osteoporosis International 26:5, pages 1477-1489.
Crossref
Crossref
Antonio Pérez, Pedro Mezquita Raya, Antonio Ramírez de Arellano, Teresa Briones, Barnaby Hunt & William J. Valentine. (2015) Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin. Diabetes Therapy 6:1, pages 61-74.
Crossref
Crossref
Charalampos Tzanetakos, Andreas Melidonis, Christos Verras, Georgia Kourlaba & Nikos Maniadakis. (2014) Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Services Research 14:1.
Crossref
Crossref
Asrul Akmal Shafie, Vishal Gupta, Ranya Baabbad, Eva Hammerby & Philip Home. (2014) An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. Diabetes Research and Clinical Practice 106:2, pages 319-327.
Crossref
Crossref
Stephen T. Brown, Daniel Grima Grima & Luc Sauriol. (2014) Cost-effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics 36:11, pages 1576-1587.
Crossref
Crossref
Adam Lundqvist, Katarina Steen Carlsson, Pierre Johansen, Emelie Andersson & Michael Willis. (2014) Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations. PLoS ONE 9:10, pages e110235.
Crossref
Crossref
José Miguel González-Clemente. (2014) Nuevos fármacos para la diabetes mellitus tipo 2: amigos o enemigos. Reflexiones sobre una nueva guía de «armonización» del tratamiento de la diabetes mellitus tipo 2. Avances en Diabetología 30:4, pages 91-94.
Crossref
Crossref
C. B. Giorda, A. Nicolucci, F. Pellegrini, C. K. Kristiansen, B. Hunt, W. J. Valentine & G. Vespasiani. (2014) Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term cost-effectiveness analysis. Diabetic Medicine 31:5, pages 615-623.
Crossref
Crossref
L. Si, T. M. Winzenberg & A. J. Palmer. (2013) A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporosis International 25:1, pages 51-60.
Crossref
Crossref
Pedro Mezquita Raya, Antonio Pérez, Antonio Ramírez de Arellano, Teresa Briones, Barnaby Hunt & William J. Valentine. (2013) Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin. Diabetes Therapy 4:2, pages 417-430.
Crossref
Crossref
Lizheng Shi, Tina Kaur Thethi & Yingnan Zhao. (2013) Diabetes risk assessment models: We have the base, but not enough?. Journal of Diabetes and its Complications 27:4, pages 305-306.
Crossref
Crossref
Andrew J. Palmer. (2013) Computer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount Hood Challenge Meeting. Value in Health 16:4, pages 670-685.
Crossref
Crossref
R. F. Pollock, G. Muduma & W. J. Valentine. (2012)
Evaluating the cost‐effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the
UK
. Diabetes, Obesity and Metabolism 15:2, pages 121-129.
Crossref
Crossref
Bob JH van Kempen, Bart S Ferket, Albert Hofman, Ewout W Steyerberg, Ersen B Colkesen, S Matthijs Boekholdt, Nicholas J Wareham, Kay-Tee Khaw & MG Myriam Hunink. (2012) Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model. BMC Medicine 10:1.
Crossref
Crossref
Richard F. Pollock, Bradley H. Curtis, Jayne Smith-Palmer & William J. Valentine. (2012) A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin. Advances in Therapy 29:12, pages 1051-1066.
Crossref
Crossref
Behnam Sharif, Jacek A. Kopec, Hubert Wong, Philippe Finès, Eric C. Sayre, Ran R. Liu & Michael C. Wolfson. (2012) Uncertainty Analysis in Population-Based Disease Microsimulation Models. Epidemiology Research International 2012, pages 1-14.
Crossref
Crossref
Andreas Liebl, Vinay Prusty, Paul Valensi, Ryuzo Kawamori, Jens Sandahl Christiansen, Andrew J. Palmer, Per Balschmidt, Robert Ligthelm & Viswanathan Mohan. (2012) Ten Years of Experience with Biphasic Insulin Aspart 30. Drugs 72:11, pages 1495-1520.
Crossref
Crossref
Shital Kamble, Kevin A. Schulman & Shelby D. Reed. (2012) Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States. Value in Health 15:5, pages 632-638.
Crossref
Crossref
Ulla K. Griffiths, Benedict Anigbogu & Kiran Nanchahal. (2012) Economic Evaluations of Adult Weight Management Interventions. Applied Health Economics and Health Policy 10:3, pages 145-162.
Crossref
Crossref
M. J. Davies, B. D. Chubb, I. C. Smith & W. J. Valentine. (2012) Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in Type 2 diabetes mellitus. Diabetic Medicine 29:3, pages 313-320.
Crossref
Crossref
R. L. Dobbins, R. O’Connor‐Semmes, A. Kapur, C. Kapitza, G. Golor, I. Mikoshiba, W. Tao & E. K. Hussey. (2011) Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes, Obesity and Metabolism 14:1, pages 15-22.
Crossref
Crossref
Li Yang, Torsten Christensen, Fengyu Sun & Jinghua Chang. (2012) Cost-Effectiveness of Switching Patients with Type 2 Diabetes from Insulin Glargine to Insulin Detemir in Chinese Setting: A Health Economic Model Based on the PREDICTIVE Study. Value in Health 15:1, pages S56-S59.
Crossref
Crossref
William J. Valentine, Andrew J. Palmer, Morten Lammert, Jakob Langer & Michael Brändle. (2011) Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents. Clinical Therapeutics 33:11, pages 1698-1712.
Crossref
Crossref
Nicolai Lohse, Elliot Marseille & James G. Kahn. (2011) Development of a model to assess the cost‐effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus. International Journal of Gynecology & Obstetrics 115:S1.
Crossref
Crossref
Gordon Goodall, María Costi, Louise Timlin, Jesús Reviriego, José Antonio Sacristán, Jayne Smith-Palmer & Tatiana Dilla. (2011) Coste-efectividad de exenatida en comparación con insulina glargina en pacientes con obesidad y diabetes mellitus tipo 2 en España. Endocrinología y Nutrición 58:7, pages 331-340.
Crossref
Crossref
Gordon Goodall, María Costi, Louise Timlin, Jesús Reviriego, José Antonio Sacristán, Jayne Smith-Palmer & Tatiana Dilla. (2011) Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinología y Nutrición (English Edition) 58:7, pages 331-340.
Crossref
Crossref
J T Cross, D L Veenstra, J S Gardner & L P Garrison. (2011) Can Modeling of Health Outcomes Facilitate Regulatory Decision Making?: The Benefit?Risk Tradeoff for Rosiglitazone in 1999 vs. 2007. Clinical Pharmacology & Therapeutics 89:3, pages 429-436.
Crossref
Crossref
William J. Valentine, Mark Aagren, Mattias Haglund, Åsa Ericsson & Manuela H. Gschwend. (2010) Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scandinavian Journal of Public Health 39:1, pages 79-87.
Crossref
Crossref
Carl Asche, Joanne LaFleur & Christopher Conner. (2011) A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes. Clinical Therapeutics 33:1, pages 74-109.
Crossref
Crossref
James L. Palmer, Amélie Beaudet, Jeremy White, Juliette Plun-Favreau & Jayne Smith-Palmer. (2010) Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Advances in Therapy 27:11, pages 814-827.
Crossref
Crossref
Roger Gadsby. (2010) The future use of liraglutide: Implications of the LEAD-2 study for treatment guidelines in type 2 diabetes. Primary Care Diabetes 4:3, pages 139-144.
Crossref
Crossref
Won Chan Lee, Christopher Conner & Mette Hammer. (2010) Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clinical Therapeutics 32:10, pages 1756-1767.
Crossref
Crossref
Sandra L. Tunis, Luc Sauriol & Michael E. Minshall. (2010) Cost Effectiveness of Insulin Glargine plus Oral Antidiabetes Drugs Compared with Premixed Insulin Alone in Patients with Type 2 Diabetes Mellitus in Canada. Applied Health Economics and Health Policy 8:4, pages 267-280.
Crossref
Crossref
Jeremy D. Goldhaber-Fiebert, Natasha K. Stout & Sue J. Goldie. (2010) Empirically Evaluating Decision-Analytic Models. Value in Health 13:5, pages 667-674.
Crossref
Crossref
Wenying Yang, Alexey Zilov, Pradana Soewondo, Ole Molskov Bech, Fawzia Sekkal & Philip D. Home. (2010) Observational studies: going beyond the boundaries of randomized controlled trials. Diabetes Research and Clinical Practice 88, pages S3-S9.
Crossref
Crossref
J. Smith‐Palmer, B. H. Curtis, K. S. Boye, G. Goodall & S. R. Pillemer. (2010) Anti‐CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis. Diabetic Medicine 27:2, pages 189-196.
Crossref
Crossref
Jason R. YoungCarrie Mcadam-Marx. (2010) Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog. Clinical Medicine Insights: Endocrinology and Diabetes 3, pages CMED.S5330.
Crossref
Crossref
Robyn de Verteuil & Woan Shin Tan. (2010) Self-monitoring of blood glucose in type 2 diabetes mellitus: systematic review of economic evidence. JBI Library of Systematic Reviews 8:7, pages 302-342.
Crossref
Crossref
Robyn de Verteuil & Woan Shin Tan. (2010) Self-monitoring of blood glucose in type 2 diabetes mellitus: systematic review of economic evidence. JBI Database of Systematic Reviews and Implementation Reports 8:7, pages 302-342.
Crossref
Crossref
Lois G. Kim & Simon G. Thompson. (2009) Uncertainty and validation of health economic decision models. Health Economics 19:1, pages 43-55.
Crossref
Crossref
Werner A Scherbaum, Gordon Goodall, Katrina M Erny-Albrecht, Massimo Massi-Benedetti, Erland Erdmann & William J Valentine. (2009) Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Effectiveness and Resource Allocation 7:1.
Crossref
Crossref
Gordon Goodall, Eric M Sarpong, Clarice Hayes & William J Valentine. (2009) The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocrine Disorders 9:1.
Crossref
Crossref
Sean D. Sullivan, Rafael Alfonso‐Cristancho, Chris Conner, Mette Hammer & Lawrence Blonde. (2012) A Simulation of the Comparative Long‐term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29:11, pages 1280-1288.
Crossref
Crossref
Kyoung Hee Lee, Se Jin Seo, Jayne Smith-Palmer, James L. Palmer, Jeremy White & William J. Valentine. (2009) Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea. Value in Health 12, pages S55-S61.
Crossref
Crossref
T. Mittendorf, J. Smith-Palmer, L. Timlin, M. Happich & G. Goodall. (2009) Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes, Obesity and Metabolism 11:11, pages 1068-1079.
Crossref
Crossref
Sandra L. Tunis. (2009) A Cost-Effectiveness Analysis to Illustrate the Impact of Cost Definitions on Results, Interpretations and Comparability of Pharmacoeconomic Studies in the US. PharmacoEconomics 27:9, pages 735-744.
Crossref
Crossref
Michiel W. van der Linden, Arian W. Plat, Joelle A. Erkens, Martha Emneus & Ron M.C. Herings. (2009) Large Impact of Antidiabetic Drug Treatment and Hospitalizations on Economic Burden of Diabetes Mellitus in The Netherlands during 2000 to 2004. Value in Health 12:6, pages 909-914.
Crossref
Crossref
C. Pratoomsoot, H. T. Smith, A. Kalsekar, K. S. Boye, J. Arellano & W. J. Valentine. (2009) An estimation of the long‐term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. Diabetic Medicine 26:8, pages 803-814.
Crossref
Crossref
Meaghan St Charles, Peter Lynch, Claudia Graham & Michael E. Minshall. (2009) A Cost-Effectiveness Analysis of Continuous Subcutaneous Insulin Injection versus Multiple Daily Injections in Type 1 Diabetes Patients: A Third-Party US Payer Perspective. Value in Health 12:5, pages 674-686.
Crossref
Crossref
Roger A. EdwardsAlan GrahamMelissa WilliamsMike AmatiCaroline WrightMei LeeDan WalshNick Hughes. (2009) Quantifying a Strategic View of Diabetes Technology Impacts: A System Dynamics Approach. Diabetes Technology & Therapeutics 11:7, pages 411-418.
Crossref
Crossref
Meaghan E.St. Charles, Hamid Sadri, Michael E. Minshall & Sandra L. Tunis. (2009) Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. Clinical Therapeutics 31:3, pages 657-667.
Crossref
Crossref
William J. Valentine, Daniel Tucker, Cheryl Silberman, Michael E. Minshall, Andrew J. Palmer & Volker Foos. (2009) Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive. Value in Health 12:1, pages 1-9.
Crossref
Crossref
Julia M. Bottomley & Frank D. Raymond. (2009) Pharmaco-economic issues for diabetes therapy. Insulin 4:1, pages 32-60.
Crossref
Crossref
P. D. Home. (2008) Impact of the UKPDS—an overview. Diabetic Medicine 25:s2, pages 2-8.
Crossref
Crossref
James L. Palmer, Meaghan Gibbs, Huib WKFH Scheijbeler, Robert W. Kotchie, Steffen Nielsen, Jeremy White & William J. Valentine. (2008) Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Advances in Therapy 25:8, pages 752-774.
Crossref
Crossref
Elise M. Pelletier, Paula J. Smith, Kristina S. Boye, Derek A. Misurski, Sandra L. Tunis & Michael E. Minshall. (2012) Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting. Applied Health Economics and Health Policy 6:2-3, pages 103-112.
Crossref
Crossref
G. Goodall, J. H. Jendle, W. J. Valentine, V. Munro, A. B. Brandt, J. A. Ray, S. Roze, V. Foos & A. J. Palmer. (2008) Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. International Journal of Clinical Practice 62:6, pages 869-876.
Crossref
Crossref
Sandra L. TunisMichael E. Minshall. (2008)
The Impact of Clinical Trial Design on Cost-Effectiveness Analyses: Illustration from a Published Study of the One-Touch
®
Ultrasmart
®
Blood Glucose Meter for Insulin-Using Diabetes Patients
. Diabetes Technology & Therapeutics 10:3, pages 227-231.
Crossref
Crossref
William J. Valentine, Gordon Goodall, Mark Aagren, Steffen Nielsen, Andrew J. Palmer & Katrina Erny-Albrecht. (2008) Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Advances in Therapy 25:6, pages 567-584.
Crossref
Crossref
Suphachai Chirakup, Nathorn Chaiyakunapruk, Usa Chaikledkeaw, Petcharat Pongcharoensuk, Boonsong Ongphiphadhanakul, Stephane Roze, William J. Valentine & Andrew J. Palmer. (2008) Cost-Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand. Value in Health 11, pages S43-S51.
Crossref
Crossref
Jae-Hyoung Cho, Jin-Hee Lee, Jeong-Ah Oh, Mi-Ja Kang, Yoon-Hee Choi, Hyuk-Sang Kwon, Sang-Ah Chang, Bong-Yun Cha, Ho-Young Son & Kun-Ho Yoon. (2008) Complication Reducing Effect of the Information Technology-Based Diabetes Management System on Subjects with Type 2 Diabetes. Journal of Diabetes Science and Technology 2:1, pages 76-81.
Crossref
Crossref
Displaying 200 of 213 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list